ELIGARD At A Glance

ELIGARD At A Glance

ELIGARD is indicated for the palliative treatment
of advanced prostate cancer

Administration2
Subcutaneous Injection Type
injectsitmanlegend.jpg
Dosing2

Dosing Information for Eligard

 

Powerful Testosterone Suppression

Testosterone Level (ng/dL) Achieved Across All Doses at Study Conclusion2

TsuppressArrowsWeb_FlatB.png

Drug Delivery

The ATRIGEL® Delivery System Providing Controlled Release1

Eligard drug delivery system

 

Storage2

Store at 2 – 8 °C (35.6 – 46.4 °F). Once outside the refrigerator this product may be stored in its original packaging at room temperature 15 – 30 °C (59 – 86 °F) for up to eight weeks prior to mixing and administration.

Contraindications2
  • Known hypersensitivity to GnRH, GnRH agonist analogs or any of the components of ELIGARD®. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature.
Warnings and Precautions2
  • Tumor Flare: Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet  obstruction, ureteral obstruction, or spinal cord compression.  Monitor patients at risk closely and manage as appropriate
  • Hyperglycemia and diabetes: Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and/or glycosylated hemoglobin (HbA1c) and manage according to current clinical practice
  • Cardiovascular diseases: Increased risk of myocardial infarction, sudden cardiac death and stroke has been reported in men. Monitor for cardiovascular disease and manage according to current clinical practice
  • Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits
  • Embryo-Fetal ToxicityBased on findings in animal studies and mechanism of action, leuprolide acetate may cause fetal harm when administered to a pregnant woman
  • ConvulsionsHave been observed in patients with or without a history of predisposing factors. Manage convulsions according to current clinical practice 
Tap for safety information

IMPORTANT SAFETY INFORMATION

ELIGARD® is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH analogs in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.

INDICATION

ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

Please see full Prescribing Information for ELIGARD.

References

  1. Sartor O. Eur Urol. 2006
  2. ELIGARD® (leuprolide acetate) for injectable suspension 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: Tolmar Therapeutics, Inc.; 2019.
  3. Prettyman J. Urologic Nursing 2019